Page 67 - அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) PRESS RELEASE Immunocore presents phase 3 data comparing tebentafusp with investigator s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting Tebentafusp is the first investigational therapy to improve Overall Survival (OS) in patients with metastatic uveal melanoma First positive Phase 3 clinical trial for any T cell receptor therapeutic and first for any bispecific in a solid tumor (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented data from a phase 3 randomized trial comparing tebentafusp (IMCgp100) with investigator s choice in first-line metastatic uveal melanoma (mUM) in the clinical trial plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Baden wubergUnited statesMarcuso butlerJessicac hasselImmunocore immDebra nielsenClayton robertsonHead of communicationsExchange commission onUniversity hospital heidelbergExchange commissionPrincess margaret cancer centreCompany annual report on formAmerican association for cancer researchOriented innovative clinical researchConsilium strategic communications